Brief: Oncosec Announces First Patient Dosed In Phase 2 Trial Of Tavo Plus Opdivo As Neoadjuvant Therapy For Melanoma
08/01/2021 17:26
Jan 8 (Reuters) - OncoSec Medical Inc ONCS.O :
* ONCOSEC ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 TRIAL OF
TAVO™
PLUS OPDIVO® AS NEOADJUVANT THERAPY FOR MELANOMA
Source text for Eikon: ID:nPn5D5qLFa
Further company coverage: ONCS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on OncoSec Medical Incorporated
See all newsBrief: OncoSec Medical Inc On June 15 Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
U.S. STOCKS ON THE MOVE-Domino's, Aldeyra, MicroVision
Brief: OncoSec Medical Files Voluntary Petition For Relief Under Provisions Of Chapter 7 Of Title 11 Of United States Code
Brief: OncoSec Medical Terminates George Chi For Cause As Employee, CFO
Brief: Oncosec Medical Receives Non Compliance Notice From Nasdaq